目的评价尿透明质酸检测应用于膀胱癌诊断和术后随访的价值。方法 70例不同分级和分期膀胱癌患者、23例泌尿系统良性疾病患者留尿,采用放射免疫法检测尿HA。结果 70例膀胱癌患者尿透明质酸(HA)含量中位值为197.4μg/L,23例泌尿系统良性疾病患者尿中HA含量中位值为112.1μg/L,两者差异有统计学意义(P<0.05)。初发肿瘤患者尿HA含量中位值为211.2μg/L,复发患者中位值为183.2μg/L,两者差异无统计学意义(P<0.05)。G2、G3组的HA检测值较G1组高,有统计学差异(P<0.05),但G2、G3组间无统计学差异(P>0.05)。pTa、pT1、pT2及以上组间HA诊断敏感性无统计学差异(P>0.05)。结论用放射免疫法检测尿HA含量操作简单,结果客观,检测迅速,准确性和灵敏性均较高,且相对廉价,可以应用于膀胱癌的筛查中。 Objective To evaluate the diagnostic value of urinary hyaluronic acid (Hyaluronic acid) in bladder cancer and its follow-up. Methods Totally 70 patients with different stages and stages of bladder cancer and 23 patients with benign diseases of the urinary system were enrolled in this study. Urinary HA was detected by radioimmunoassay. Results The median urinary HA level of 70 bladder cancer patients was 197.4 μg / L, and that of 23 urinary tract benign diseases patients was 112.1 μg / L, the difference was statistically significant (P <0.05). The median urinary HA level in patients with initial tumor was 211.2 μg / L, and the median recurrence rate was 183.2 μg / L, with no significant difference between the two groups (P <0.05). There was a significant difference between HA group and G1 group (P <0.05), but there was no significant difference between G2 and G3 group (P> 0.05). The sensitivity of HA in pTa, pT1, pT2 and above groups was not significantly different (P> 0.05). Conclusion Radioimmunoassay for the detection of urinary HA content is simple, objective, rapid detection, accuracy and sensitivity are high, and relatively cheap, can be used in screening of bladder cancer.